MA53671A - Formes cristallines d'un agoniste du récepteur farnésoïde x - Google Patents

Formes cristallines d'un agoniste du récepteur farnésoïde x

Info

Publication number
MA53671A
MA53671A MA053671A MA53671A MA53671A MA 53671 A MA53671 A MA 53671A MA 053671 A MA053671 A MA 053671A MA 53671 A MA53671 A MA 53671A MA 53671 A MA53671 A MA 53671A
Authority
MA
Morocco
Prior art keywords
farnesoid
receptor agonist
crystalline forms
crystalline
forms
Prior art date
Application number
MA053671A
Other languages
English (en)
Inventor
Robert Mansfield
Nicholas D Smith
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of MA53671A publication Critical patent/MA53671A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053671A 2018-09-18 2019-09-17 Formes cristallines d'un agoniste du récepteur farnésoïde x MA53671A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862733007P 2018-09-18 2018-09-18

Publications (1)

Publication Number Publication Date
MA53671A true MA53671A (fr) 2021-07-28

Family

ID=69887984

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053671A MA53671A (fr) 2018-09-18 2019-09-17 Formes cristallines d'un agoniste du récepteur farnésoïde x

Country Status (15)

Country Link
US (1) US20210347736A1 (fr)
EP (1) EP3852749A4 (fr)
JP (1) JP2022500395A (fr)
KR (1) KR20210064261A (fr)
CN (1) CN113056270A (fr)
AU (1) AU2019344905A1 (fr)
BR (1) BR112021004931A2 (fr)
CA (1) CA3112485A1 (fr)
CL (1) CL2021000631A1 (fr)
EA (1) EA202190663A1 (fr)
IL (1) IL281464A (fr)
MA (1) MA53671A (fr)
MX (1) MX2021003083A (fr)
SG (1) SG11202102586RA (fr)
WO (1) WO2020061115A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016323992B2 (en) 2015-09-16 2021-05-06 Organovo, Inc. Farnesoid X receptor agonists and uses thereof
KR20210076910A (ko) 2018-09-18 2021-06-24 메타크린, 인크. 파르네소이드 x 수용체 효능제 및 그의 용도
TW202143962A (zh) * 2020-03-18 2021-12-01 美商梅塔克林公司 法尼醇x受體促效劑之調配物
WO2022094816A1 (fr) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Formulation solide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1914205A (zh) * 2003-12-19 2007-02-14 葛兰素集团有限公司 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
PL1734970T3 (pl) * 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
AU2007215207A1 (en) * 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
WO2010089686A1 (fr) * 2009-02-04 2010-08-12 Pfizer Inc. Dérivés de 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one
CN103391937A (zh) * 2010-12-20 2013-11-13 Irm责任有限公司 用于调控法尼醇x受体的组合物和方法
US10377717B2 (en) * 2015-09-16 2019-08-13 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
AU2016323992B2 (en) * 2015-09-16 2021-05-06 Organovo, Inc. Farnesoid X receptor agonists and uses thereof
EP3350158A4 (fr) * 2015-09-16 2019-05-08 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
JP2018536016A (ja) * 2015-09-16 2018-12-06 メタクリン,インク. ファルネソイドx受容体アゴニストとその使用
BR112018006471B1 (pt) * 2015-10-01 2024-02-27 Senomyx, Inc Composto, composição, método de modular o membro de melastina do canal potencial do receptor transitório 8 (trpm8), método de modular a sensação de resfrescância de uma composição e método de induzir uma sensação de refrescância em um ser humano ou animal
WO2017078928A1 (fr) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Agonistes de fxr et procédés de production et d'utilisation
CN110637015B (zh) * 2017-03-15 2024-04-02 奥加诺沃公司 法尼醇x受体激动剂及其用途
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
MX2021003083A (es) 2021-05-27
IL281464A (en) 2021-04-29
SG11202102586RA (en) 2021-04-29
CN113056270A (zh) 2021-06-29
CL2021000631A1 (es) 2021-10-01
BR112021004931A2 (pt) 2021-06-01
JP2022500395A (ja) 2022-01-04
EP3852749A4 (fr) 2022-08-24
KR20210064261A (ko) 2021-06-02
EA202190663A1 (ru) 2021-08-13
EP3852749A1 (fr) 2021-07-28
WO2020061115A1 (fr) 2020-03-26
AU2019344905A1 (en) 2021-04-29
CA3112485A1 (fr) 2020-03-26
US20210347736A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MA53671A (fr) Formes cristallines d'un agoniste du récepteur farnésoïde x
MA54233A (fr) Synthèse améliorée d'un intermédiaire clé du composé inhibiteur de kras g12c
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
MA51819A (fr) Nouvelles formes cristallines
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
DK3810201T5 (da) GIP/GLP1-agonist-sammensætninger
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
DK3820873T3 (da) Selektive østrogenreceptornedbrydere
DK3746609T3 (da) Tilslutningsindretning for en toiletkumme
MA50921A (fr) Sels et formes cristallines d'un modulateur allostérique positif du gabaa
DK3814341T3 (da) Erbb-receptorinhibitorer
MA46460A (fr) Formes cristallines et salines de composés agonistes de ppar
DK3603523T3 (da) Indretning til digital billeddannelse i hovedregionen af en patient
DK3820874T3 (da) Selektive estrogenreceptornedbrydere
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
IL285510A (en) modular x farnesoid receptor useful amide compounds substituted ca
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
IL281168A (en) Crystal forms of the quinazole compound and its hydrochloride salts
MA53546A (fr) Nouvelles formes salines de chlorhydrate d'un inhibiteur de kinase à structure sulfamide
EP4121010A4 (fr) Formes cristallines d'un agoniste du récepteur farnésoïde x
MA41599A (fr) Formes cristallines d'un composé pyrrolopyridine
DK3523310T3 (da) Krystallinske polymorfer af en muscarinacetylcholinreceptoragonist
PL3643704T3 (pl) Nowe produkty pośrednie do wytwarzania chlorowodorku remifentanilu
MA53918A (fr) Nouvelles utilisations d'un agoniste du récepteur 5-ht4
DK3898638T3 (da) Krystallinske former af en par4-hæmmer